2025-05-01 12:00Financial Data and Key Metrics Changes - Revenue for Q1 2025 totaled $188.8 million, a significant increase from $25.3 million in Q1 2024, primarily due to accounting impacts from the reduction in the BebteG collaboration agreements program budget [30][31] - Cash, cash equivalents, and marketable securities at the end of Q1 2025 were approximately $954 million, down from $1.04 billion at the end of 2024 [30] Business Line Data and Key Metrics Changes - The company has made progress in its clinical pipeline, including positive pivotal data for the protact degrader Vebbegastran and advancements in other programs such as ARV-102 and ARV-393 [4][5][14] - A workforce reduction of approximately one-third of the company was implemented, expected to result in annual cost reductions of about $80 million [10][11] Market Data and Key Metrics Changes - The second line plus setting for ESR1 mutant breast cancer presents a significant opportunity, with an estimated 40,000 new patients annually, of which 40% are expected to be ESR1 mutant [56][92] - The company anticipates that Vebbegastran could capture a significant portion of the market due to its best-in-class profile [41][56] Company Strategy and Development Direction - The company is focusing on maximizing efficiency and reducing operating expenses to extend its cash runway into the second half of 2028 [11][12] - The decision to remove two Phase III combination trials from the development plan was made in alignment with Pfizer, based on emerging data and discussions with health authorities [7][8][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of Vebbegastran as a best-in-class treatment for ESR1 mutant breast cancer and plans to submit a regulatory filing in the coming months [6][15] - The company is optimistic about the ongoing clinical programs and the potential for significant data inflection points in 2025 [34] Other Important Information - The company has received a safe to proceed letter from the FDA for ARV-806, its KRAS G12D degrader, with plans to begin a Phase I trial in the second half of 2025 [25][26] - The restructuring is expected to result in a total of approximately $500 million in cost savings and avoidance over the next three years [11][29] Q&A Session Summary Question: What drove the decision to not advance the four-six inhibitor combinations? - The decision was based on discussions with Pfizer and emerging data indicating that ER therapies would likely be restricted to patients with ESR1 mutations in the second line plus setting [40][41] Question: How do you view the market size for Vebdeg in the second line plus monotherapy setting? - The company estimates a significant opportunity with around 25,000 new patients annually in the second line setting, with a good profile for Vebdeg to capture a substantial market share [56][92] Question: What is the expected timeline for the pre NDA meeting with the FDA? - The company has already met with the FDA for the pre NDA meeting and is clear to move forward with the submission [109] Question: When can we expect the next data update from the LRRK2 program? - The company expects to share information later in the year, with ongoing studies in patients with Parkinson's disease [109]